Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
60 Cards in this Set
- Front
- Back
what makes up the striatum
|
caudate nucleus + putamen
|
|
define parkinsonism
|
degen. of dopaminergic neurons of the substantia nigra-so deficit of inhib. on cholinergic
|
|
D1 path aka..
what does it do? |
direct pathway-stimulates motor activity
|
|
D2 path aka
|
indirect pathway-dopamine acting on this inhibits the indirect pathway(takes brake off)..think disinhibition
|
|
maximal efficacy occurs when...
|
both d1 and d2 are occupied by dopamine
|
|
rate of neuron loss per decade
|
3-15% per decade-we are in 3rd decade of life
|
|
percent to be considered having parkinsons
|
80% or >
|
|
D1 like receptors
|
D1 and D5
|
|
D2 like
|
D2,3,4
|
|
Which receptor in striatum?
PFC? |
striatum-D1, D2
PFC-D1 |
|
#1 excitatory neurotransm.
#1 inhinib? |
Glutamate-excit
GABA-inhib |
|
structures involved in finetuning
|
Extrapyramidal NS.-Thalamus
|
|
Niagra striatal pathway is involved in?
|
movement
|
|
Dopamine's effects
|
D1-motion
D2-inhibits brake(motion) Ach- inhibits brake |
|
R.L. step of dopamine synth.
|
tyrosine hydrolase
|
|
MAO-A where? and what?
MAO-B-where and what? |
A-in liver-NE, 5HT, DA
B-brain-DA |
|
how does L-dopa reach brain?
|
actively transp. by LNAAT in epithelium and brain
|
|
dopa decarboxylase requires what? and what does it do?
|
requires coenzyme vit b-6
converts L-dopa to dopamine(can prematurely convert it in liver) |
|
COMT does what?
|
can convert L-dopa to inactive metab. which competes for transporter
|
|
what kind of changes in behavior for park?
|
initiall change-sad to happy (low dope to high)
|
|
L-dopa makes dopamine which inhibits?
|
prolactin(hypoprolactemia) in A.Pituit.
|
|
most effect. tx for park?
|
L-dopa 50% incr.
|
|
4 cardinal sytmptoms of park?
|
-resting tremor
-pill rolling-first sign -akinesa -cogwheel rigidity |
|
mental ability of park patients? affect or not?
|
not impaired
|
|
parkinsons disease is a ______ disease
|
idiopathic
but maybe due to toxins-MPTP, CO2 posioning, manganese |
|
carbidopa, what does it do and where?
|
inhibits decarboxylation peripherally-can't cross BBB(good)
prevents premature conversion of L-DOPA |
|
MAO-A, B which one can be combined with dopa?
|
B- if A is used you prevent breakdown of Dopamine--->NE so cause hypertensive crisis
|
|
pt taking just dopa causes?
|
N+V-from D2 in CTZ
|
|
relief from dopa lasts for how long
|
5 years
|
|
how to tx wearing off or end dose akinesia?
|
smaller dose or more frequent intervals or CR
|
|
On-off phenomenon is
|
NOT simply blood leveles
|
|
Drug holiday for S.E.
|
may help in dopa tx S.E. but little help for on-off phenom.
No longer reccom. |
|
Where is COMT found?
|
gut, liver, brain
|
|
benztropoine and trihexyphenidyl
|
prototype anticholinergic drugs for parkinsons
all same efficacy-improve tremor |
|
Amandtadine
|
mainly blocks NMDA
increases presynaptic dopamine, mild anticholinergic effects can be mono, usually adjunct therapy not metabolizes-kidney excretes S.E.-purpleish skin limited effectivness-6 to 9 months |
|
blocking NMDA benefits what?
|
effect on ridgity + akinesia
anti-dyskinesic due to NMDA block |
|
Bromocriptine
|
D2 receptor agonist, mild D1 antag
t1/2 is 4 x than Dopa fewer long-term motor fluctuations eventually benefits decrease |
|
S.E. of Bromoctriptine
|
Orthost hypotension
syncope(fainting) N+V-D2 hallucinations-reason ppl discontinue pedal edema |
|
Pramipexole and ropinirole
|
non-ergot dopaminergic agonist
-D2 and D3 approved for early and advanced pakinsons -Same S.E. as bromocriptine causes sudden sleep atacks-all dopamine agonists too |
|
Apomorphine
|
non-ergot dopamine agonist
-tx of hypomobility(off episodes) |
|
S.E. of apomorphine
|
N+V, must be taken with anti-emetic like Tigan
increased woody-Europe contra-ondansetron + 5hts recp antag. contains sulfites |
|
Rotigotine
|
non ergot dopamine agonist, D2
also at D1, D3 first patch form, for parkinsons |
|
Adv. of DA agonists vs L-Dopa
|
no comp with AA for LNAAT
no metab. for activation incr reliability, potency(not efficacy) dec. risk of dyskinesias metab. does NOT prod free radicals |
|
Tolcapone and Entacapone
|
revers. COMT inhibitors
prevent conversion of Levodopa to inactive 3-O-methyldopa, competes for transport |
|
3-O-methyldopa
|
inactive levodopa, half-life is *15 hours*
|
|
COMT inhib.
|
Tolcapone-inhibit in CNS and Periph.
Entacapone-inhibit in periph. used for adjunct therapy |
|
Tolcapone S.E. (think TACOS)
|
explosive diarrhea
hepatotoxicity-discontinue use if levels >5 |
|
Selegline
|
formerly deprenyl
MAO-B inhib. high does-loses specificity monotherp.-only works for months mainly adjunct |
|
Selegline S.E.
|
metabolized into amphetamines-insomnia if does after 2pm
dyskinesia, confusion, psychosis |
|
Anti-oxidant drugs that counteract dopamine oxidation
|
MAO-B inhib
Vit. E |
|
Oxid of dopamine via MAO leads to
|
free radicals....H202-->OH*(free radical)
|
|
Rasagline
|
MAO-B inhib. (14x more selective for B)
5x more potent than selegiline **NOT metab to amphetamine** metabolized by CYP A12 |
|
most eff Early tx of parkinsons
dopamine agonists vs levodopa |
dopamine <levodopa
|
|
dopamine agonists are more likely to produce ________ and less likely to produce_________
|
neuropsychiatric problems
dyskinesias |
|
define Tic
|
repetitive motion
can be partially suppressed by voluntarily controlled |
|
define chorea
|
rapid, flick-like movements of limbs-like restlessness
|
|
athetosis
|
slow, writing movements of extremities
|
|
ballismus
|
violent, flailing movements-proximal limbs
|
|
postural tremor
|
maximal when limb is in static motion-arms stretched out in bird wing
associated with hyperadrenergic states-from amphetamines, cocaine gener. and abated by peripherie adrenergic blocked by propanolol-B1 and B2! |
|
kinetic(intention) tremor
|
maximal when in movement, NOT at rest
|